Glioma, Malignant Clinical Trial
Official title:
Exploring the Feasibility of the Molecular Pathology Model of Patients With Glioma Via Retrospective Research
Evaluate the diagnostic value of TERT promoter mutation in differ glioma subtypes and expend the application of the diagnostic algorithm to surgical practice
A total of 976 gliomas were enrolled in this study. First, in order to evaluate the diagnostic value of TERT promoter mutation in differ glioma subtypes, we conducted a retrospective cohort study included 753 frozen tissue samples of patients with different grades of glioma. According to WHO CNS5, all recommended alteration including IDH, 1p/19q, TERT, EGFRamp and 7+/10- were profiled using multiple approaches and a permanent diagnosis was obtained for each patient. Exploring the feasibility of the molecular pathology model of patients with glioma via retrospective research. Compare with the existing molecular pathology system, analyze the combination of IDH and TERT mutations and the feasibility of stratifying the prognosis of patients with glioma. Moreover, to expend the application of the diagnostic algorithm to surgical practice, we developed a fast detection assay that could detect hotspot somatic mutations in IDH and TERT within 25 minutes and can discriminate TERT and IDH mutations from wild-type alleles with a minimum variant allele frequency (VAF) of 0.2% and 0.5%, respectively. We further validate the simplified diagnostic algorithm on frozen tissue of 223 patients with glioma in another retrospective cohort and performed this assay to evaluate the accuracy of the rapid assay. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05557240 -
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
|
N/A | |
| Recruiting |
NCT05485038 -
General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
|
N/A | |
| Recruiting |
NCT05474573 -
Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
|
N/A | |
| Active, not recruiting |
NCT04547621 -
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
| Completed |
NCT05806619 -
Glioma: Biomolecular Aspects
|
||
| Not yet recruiting |
NCT04562077 -
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
|
||
| Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
| Completed |
NCT04497142 -
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05656053 -
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
|
||
| Recruiting |
NCT06196918 -
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
|
N/A | |
| Recruiting |
NCT05556486 -
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
|
||
| Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
| Recruiting |
NCT05773326 -
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
|
Early Phase 1 | |
| Active, not recruiting |
NCT05063682 -
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
|
Phase 1 | |
| Completed |
NCT05100602 -
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
|
||
| Completed |
NCT05100173 -
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
|
||
| Recruiting |
NCT05182905 -
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
|
Early Phase 1 | |
| Recruiting |
NCT06381726 -
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
|
N/A |